Mapping our History, Building a
Transformative Future

From our start in Beijing with a handful of scientists and developers, each committed to discovering new oncology treatments, improving access focused on helping patients in China...

To today, with a global team, a rich pipeline, strong partnerships, and commercial products.

We have no borders.

Except as otherwise indicated, products have not been approved for marketing and their safety and efficacy have not been established in any jurisdiction.

BeiGene Co-Founders, John V. Oyler and Xiaodong Wang, Ph.D.

2010

2010

  • BeiGene was founded as a research and development company
BeiGene R&D Center

2011

2011

  • Established the first R&D center in Beijing
  • Initiated PARP and RAF discovery programs
Immuno-oncology Therapies

2012

2012

  • Initiated PD-1 and BTK discovery programs 
Clinical development in Australia

2013

2013

  • Began clinical development of lifirafenib in Australia
Clinical Researcher

2014

2014

  • Began clinical development of pamiparib and zanubrutinib in Australia
BeiGene opens first US office

2015

2015

  • Began clinical development in China
  • Expanded into the U.S. with the first office established in Cambridge, MA
First China biotech to go public on the Nasdaq

2016

2016

  • Became the first Chinese-born biotech to go public on Nasdaq with a $182 million IPO
  • Completed construction of the Suzhou small molecule manufacturing facility
Collaboration with Celgene

2017

2017

  • Initiated the first global Phase 3 registrational trial of zanubrutinib
  • Entered global strategic immuno-oncology collaboration with Celgene on tislelizumab
  • Absorbed Celgene’s commercial operation in China
BeiGene expands global operations

2018

2018

  • Established first European office in Switzerland
  • Completed dual primary listing on Hong Kong Stock Exchange with a $902 million IPO
  • Expanded into Europe with opening of the Basel office
  • Secured National Reimbursement in China for both Revlimid® and Vidaza®
Established research institute

2019

2019

  • Received first FDA approval for BRUKINSA® (zanubrutinib)
  • Received first approval for tislelizumab in China
  • Entered a global strategic collaboration with Amgen
  • Completed the initial phase of BeiGene Guangzhou Bio-Manufacturing Base
  • Established BeiGene Suzhou Research Institute
Clinical development

2020

2020

  • Received first approvals for BRUKINSA® in China
  • Received additional approvals for tislelizumab in China
  • Completed a registered direct offering of approx. $2.07 billion
  • Submitted the first new drug application for pamiparib in China

REVLIMID®, VIDAZA®, and ABRAXANE® are registered trademarks of Celgene Corporation. 

1VIDAZA was approved in China in April 2017 for the treatment of intermediate-2 and high-risk myelodysplastic syndromes, chronic myelomonocyte leukemia, and acute myeloid leukemia 20% to 30% blasts and multi-lineage dysplasia.

2REVLIMID was approved in China in 2013 for the treatment of multiple myeloma, or MM, in combination with dexamethasone in adult patients who have received at least one prior therapy. On February 2, 2018, REVLIMID was approved in China for a new indication for the treatment of MM in combination with dexamethasone in adult patients with previously untreated MM who are not eligible for transplant.

3ABRAXANE was approved in China in 2009 for metastatic breast cancer after failure of combination chemotherapy for metastatic disease or relapse within six months of adjuvant chemotherapy. Prior therapy should have included an anthracycline unless clinically contraindicated.

Join our Team

We’re a dynamic company, with a bold vision and bright future. We’re looking for highly motivated colleagues who can collaborate with us as we build a company that will have a lasting impact in the global fight against cancer.

Our Science

Our focus is on molecularly-targeted and immuno-oncology cancer therapeutics as both monotherapies and for use in combination treatments to have a meaningful and lasting impact on cancer patients.

X